Introduction: Hematopoietic neoplasms represent a public health concern, as they are the most common type of cancer in children worldwide. Patients afflicted with this illness often face various complications, including resistance to the available therapy regimens and severe associated side effects, as well as frequent relapses and emotional distress. In light of these challenges, there is an urgent need for intensified research focused on early diagnosis and more precise therapeutic targeting. From this perspective, long non-coding RNAs (lncRNAs) are recognized for their multiple functions in cellular metabolism and their key involvement in cancer biology. Among them, lncRNA KIAA0125 has been proposed as a potential biomarker for prognosis prediction and risk stratification in Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) of B (B-ALL) and T (T-ALL) cells, thus highlighting its promise as a research target to improve the therapeutic landscape of AL. Objectives: The present study aimed to evaluate the impact of KIAA0125 expression levels on patients with AL. Methods: For this research, 91 peripheral blood (PB) or bone marrow samples from AL patients (AML = 10; ALL = 81; B-ALL = 70; T-ALL = 11) and 8 PB samples from healthy volunteers (CAAE = 30307820.7.0000.5634) were used. Groups consisted of individuals aged 0 to 17 years, of both sexes. RNA was extracted from the samples using TRIzol Reagent® and converted into cDNA using High-Capacity cDNA Reverse Transcription® kit. Gene expression was evaluated via RT-qPCR, using the TaqMan® probe system for KIAA0125 and reference genes ACTB (Hs01060665_g1) and ABL1 (Hs01060665_g1). Then, the mean cycle threshold (Ct), ?Ct, and fold change (FC) were calculated. Normality was assessed using the Shapiro–Wilk and D’Agostino–Pearson tests, and Student’s t-test or Welch test were used to evaluate differences in global expression levels between patients and healthy controls. Statistical significance was set at p ? 0.05, and analyses were conducted using PSPP v2.0.0 and Endogene Analyzer software. Results: The mean ?Ct in the control group was 3.94 ± 1.23 cycles, lower than ALL (6.83 ± 3.10) and AML (8.10 ± 2.93) patients. Further analysis of ALL subtypes revealed that the mean ?Ct for B-ALL (6.75 ± 3.16) was higher than that of T-ALL (5.42 ± 2.81). Such variations became even more evident when evaluating FC between groups, with the mean being higher for AML (0.06 ± 1.30) than for ALL (0.15 ± 5.20). Additionally, B-ALL (0.14 ± 5.59) cases presented a lower mean value than T-ALL (0.35 ± 0.69). When comparing the differential global expression of KIAA0125 among AML, ALL and control groups, a statistically significant reduction in gene expression was observed in both AML (p = 0.0025) and ALL (p = 6.056e-05) groups. As demonstrated in previous analyses, a statistically significant difference was found when comparing expression levels between controls and B-ALL (p = 5.418e-05) and T-ALL (p = 0.0142) groups. Conclusion: Thus, our results suggest that KIAA0125 expression is significantly suppressed in the analyzed pediatric acute leukemia cases, indicating that this lncRNA is a promising biomarker candidate for the disease.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
